Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.

Tumor slices cancer ex vivo models immuno-oncology syngeneic model

Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
Historique:
received: 04 05 2019
revised: 31 08 2019
accepted: 13 09 2019
entrez: 20 11 2019
pubmed: 20 11 2019
medline: 20 11 2019
Statut: epublish

Résumé

Organotypic tumor slices represent a physiologically-relevant culture system for studying the tumor microenvironment. Systematic characterization of the tumor slice culture system will enable its effective application for translational research. Here, using flow cytometry-based immunophenotyping, we performed a comprehensive characterization of the immune cell composition in organotypic tumor slices prepared from four syngeneic mouse tumor models and a human liver tumor. We found that the immune cell compositions of organotypic tumor slices prepared on the same day as the tumor cores were harvested are similar. Differences were primarily observed in the lymphocyte population of a clinical hepatocellular carcinoma case. Viable populations of immune cells persisted in the tumor slices for 7 days. Despite some changes in the immune cell populations, we showed the utility of mouse tumor slices for assessing responses to immune-modulatory agents. Further, we demonstrated the ability to use patient-derived xenograft tumor slices for assessing responses to targeted and cytotoxic drugs. Overall, tumor slices provide a broadly useful platform for studying the tumor microenvironment and evaluating the preclinical efficacy of cancer therapeutics.

Identifiants

pubmed: 31741771
doi: 10.1080/2162402X.2019.1670019
pii: 1670019
pmc: PMC6844320
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e1670019

Subventions

Organisme : NCI NIH HHS
ID : K22 CA201229
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States

Informations de copyright

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Cancer Immunol Res. 2018 Sep;6(9):1069-1081
pubmed: 30018045
EMBO Mol Med. 2017 Feb;9(2):167-180
pubmed: 27932443
J Neurosci. 1981 Mar;1(3):318-22
pubmed: 7264721
Hepatology. 2014 Apr;59(4):1415-26
pubmed: 24002931
Cancer Gene Ther. 1994 Jun;1(2):91-8
pubmed: 7621246
Development. 2017 Mar 15;144(6):946-951
pubmed: 28292839
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Mol Cell Proteomics. 2011 Apr;10(4):M110.005363
pubmed: 21296872
Biotechnol J. 2014 Sep;9(9):1115-28
pubmed: 25174503
iScience. 2018 Oct 26;8:49-53
pubmed: 30273912
Methods Mol Biol. 2019;1884:283-295
pubmed: 30465211
Front Oncol. 2018 Mar 12;8:49
pubmed: 29594035
Adv Immunol. 2007;96:41-101
pubmed: 17981204
Oncoimmunology. 2018 Jan 19;7(5):e1421891
pubmed: 29721371
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
Oncoimmunology. 2017 May 25;6(7):e1333210
pubmed: 28811976
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6
pubmed: 20404174
J Immunother. 2013 Nov-Dec;36(9):477-89
pubmed: 24145359
Cancer Res. 2014 Jan 15;74(2):632; discussion 635
pubmed: 24408925
Brain Res Bull. 1980 Jul-Aug;5(4):391-403
pubmed: 7407636
J Immunol Methods. 2018 Apr;455:71-79
pubmed: 29408707
Clin Cancer Res. 2016 May 15;22(10):2329-34
pubmed: 27016309
Future Sci OA. 2017 Mar 27;3(2):FSO190
pubmed: 28670477
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Onco Targets Ther. 2018 Nov 29;11:8543-8553
pubmed: 30555244
Microbiol Spectr. 2016 Nov;4(6):
pubmed: 27837740
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
J Vis Exp. 2017 Dec 27;(130):
pubmed: 29364247
PLoS One. 2017 Aug 17;12(8):e0182786
pubmed: 28817603
Exp Cell Res. 1994 Apr;211(2):314-21
pubmed: 8143779
Stem Cells. 1995 May;13(3):242-9
pubmed: 7613491
Blood. 2005 Jan 1;105(1):241-50
pubmed: 15345595
Cancer Cell. 2014 Dec 8;26(6):938
pubmed: 28898680
BMC Cancer. 2006 Apr 07;6:86
pubmed: 16603054
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002
PLoS One. 2016 Sep 09;11(9):e0161779
pubmed: 27610613
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Gut. 2001 Aug;49(2):251-62
pubmed: 11454803
Cancer Immunol Res. 2017 Jan;5(1):29-41
pubmed: 27923825
BMC Cancer. 2016 Feb 09;16:78
pubmed: 26860465
J Immunol Res. 2016;2016:8941260
pubmed: 27314056

Auteurs

Ramya Sivakumar (R)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Marina Chan (M)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Jiye Stella Shin (JS)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Nao Nishida-Aoki (N)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Heidi L Kenerson (HL)

Department of Surgery, University of Was hington, Seattle, WA, USA.

Olivier Elemento (O)

Englander Institute of Precision medicine, Weill Cornell Medicine, NY, USA.

Himisha Beltran (H)

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Raymond Yeung (R)

Department of Surgery, University of Was hington, Seattle, WA, USA.

Taranjit S Gujral (TS)

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Pharmacology, University of Washington, Seattle, WA, USA.

Classifications MeSH